NCT02528461View on ClinicalTrials.gov

Macrophage Activation Markers During Sofosbuvir-based Treatment Regimes of Chronic Hepatitis C

CompletedOBSERVATIONAL
Enrollment

71

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

January 31, 2019

Study Completion Date

January 31, 2020

Conditions
Hepatitis C
Interventions
DRUG

Galactose

A test to investigate the liver's ability to metabolize galactose to glucose by injecting galactose followed by measurements of blood glucose and the quantification of galactose in the urine.

PROCEDURE

Gastroscopy

PROCEDURE

Liver biopsy

PROCEDURE

Fibroscan

PROCEDURE

Liver vein catheterization

DRUG

Sofosbuvir

Trial Locations (1)

8000

Aarhus University Hospital, Aarhus C

All Listed Sponsors
collaborator

Aarhus University Hospital

OTHER

lead

University of Aarhus

OTHER

NCT02528461 - Macrophage Activation Markers During Sofosbuvir-based Treatment Regimes of Chronic Hepatitis C | Biotech Hunter | Biotech Hunter